Payment overview · 2025
General Payments
$142.15
8 reported records · 6 companies
Healthcare provider profile · identity verified
Madaline Mccray, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MOODY, AL · NPI 1700470911
Verified facts
What the public records show
CMS Open Payments records show Madaline Mccray, FNP received $142.15 in general payments during 2025 across 8 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.97 | 23.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.23 | 22.0% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $23.03 | 16.2% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.74 | 15.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.85 | 11.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.33 | 10.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $142.15 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.23 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.23 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 260 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 256 | 107 |
| Losartan Potassium | Losartan Potassium | 200 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 74 |
| Omeprazole | Omeprazole | 169 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 60 |
| Famotidine | Famotidine | 143 | 53 |
| Montelukast Sodium | Montelukast Sodium | 132 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 53 |
| Alendronate Sodium | Alendronate Sodium | 108 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 31 |
| Lisinopril | Lisinopril | 101 | 42 |
| Metformin Hcl | Metformin Hcl | 99 | 43 |
| Carvedilol | Carvedilol | 97 | 36 |
| Metformin Hcl Er | Metformin Hcl | 94 | 41 |
| Prednisone | Prednisone | 91 | 80 |
| Potassium Chloride | Potassium Chloride | 90 | 38 |
| Furosemide | Furosemide | 75 | 33 |
| Ozempic | Semaglutide | 71 | 23 |
| Trazodone Hcl | Trazodone Hcl | 69 | 29 |
| Januvia | Sitagliptin Phosphate | 64 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 42 |
| Telmisartan | Telmisartan | 59 | 23 |
| Simvastatin | Simvastatin | 55 | 24 |
| Celecoxib | Celecoxib | 54 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 16 |
| Allopurinol | Allopurinol | 51 | 24 |
| Cefuroxime | Cefuroxime Axetil | 51 | 45 |
| Jardiance | Empagliflozin | 51 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 21 |
| Atenolol | Atenolol | 50 | 17 |
| Azithromycin | Azithromycin | 49 | 45 |
| Azelastine Hcl | Azelastine Hcl | 48 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 17 |
| Ezetimibe | Ezetimibe | 45 | 21 |
| Sertraline Hcl | Sertraline Hcl | 45 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 15 |
| Methocarbamol | Methocarbamol | 38 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 28 |
| Mounjaro | Tirzepatide | 35 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | 12 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 12 |
| Buspirone Hcl | Buspirone Hcl | 31 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | 11 |
| Donepezil Hcl | Donepezil Hcl | 27 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | 12 |
| Mirtazapine | Mirtazapine | 24 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 22 | 21 |
| Fluconazole | Fluconazole | 21 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 16 |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | 14 |
| Estradiol | Estradiol | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $142.15 · 8 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AREXVY, Azstarys, Cologuard Collection Kit, JARDIANCE, TRELEGY ELLIPTA, XIFAXAN, ZTLido | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error